result in loss of
activity.
REFERENCES 1. Mol Cancer Ther. 2008 Mar;7(3):538-47.
2. J Immunol. 2008 Feb 15;180(4):2099-106.
3. J Biol Chem. 2007 Nov 30;282(48):34748-57. Epub 2007 Oct 2.
4. AIDS Res
, 5355-5360
(2007).
6. Omura, T. et al., J. Neurosci. Res., 86, 1577-1587
(2008).
7. Yang, H. et al., Exp. Cell Res., 313, 538-550
(2006).
8. Yamasaki, S. et al., EMBO J., 26, 113-122
, 5355-5360
(2007).
6. Omura, T. et al., J. Neurosci. Res., 86, 1577-1587
(2008).
7. Yang, H. et al., Exp. Cell Res., 313, 538-550
(2006).
8. Yamasaki, S. et al., EMBO J., 26, 113-122
5355-5360
(2007).
6. Omura, T. et al., J. Neurosci. Res., 86, 1577-1587
(2008).
7. Yang, H. et al., Exp. Cell Res., 313, 538-550
(2006).
8. Yamasaki, S. et al., EMBO J.
mitogenic
c Mitogenic for neuraminidase-treated lymphocytes
References
1. Biochim. et Biophys. Acta, 538, 299-315 (1978).
2. Rueben, L., et al., Activities of lectins and their
immobilized derivatives
Sigurjonsson, O., et al., PNAS (2005) 102:5227-5232.
66) Frappart, P., et al., Nature Medicine (2005) 11:538-544.
67) Peretto, P., et al., J. Comparative Neurology (2005) 487:407-427.
68) Scheffler, B., et
. Acad. Sci. USA 78:514.
8. Bridson, W. and Kohler, P. (1970). J.
Clin. Endocrinol. Metab. 30:538.
9. Colowick, S. and Kaplan, N. (1979).
Methods in Enzymology. Vol 58:99-
103.
10. Fischer
remain in
solution and are detected in a fluorescent
microplate reader (Ex. max.: ~485 nm; Em. max.:
~538 nm). Manufactured by Norzyme, Inc.
Cat. No. 539126 1 Kit
Looking for the Convenience, Consistency
113 nM, and 2.4 mM
respectively). Purity: ≥95% by HPLC. M.W. 297.3
5 mg
I-OMe-AG 538 658417 An analog of AG 538 (Cat. No. 658403) that acts as an inhibitor of IGF-1 receptor kinase
both in vitro and
NP_001171669.1 y y y
85 c-erbB-2 E2777 2064 ERBB2 M NP_001005862.1 ,NP_004439.2 , y n/d n/d
86 c-erbB-3 E8767 2065 ERBB3 M NP_001005915.1 ,NP_001973.2 y n/d n/d
87 c-erbB-4 E5900 2066 ERBB4 M NP_001036064.1
NP_001171669.1 y y y
85 c-erbB-2 E2777 2064 ERBB2 M NP_001005862.1 ,NP_004439.2 , y n/d n/d
86 c-erbB-3 E8767 2065 ERBB3 M NP_001005915.1 ,NP_001973.2 y n/d n/d
87 c-erbB-4 E5900 2066 ERBB4 M NP_001036064.1
NP_001171669.1 y y y
85 c-erbB-2 E2777 2064 ERBB2 M NP_001005862.1 ,NP_004439.2 , y n/d n/d
86 c-erbB-3 E8767 2065 ERBB3 M NP_001005915.1 ,NP_001973.2 y n/d n/d
87 c-erbB-4 E5900 2066 ERBB4 M NP_001036064.1
5 mg
I-OMe-AG 538 658417 [a-Cyano-(3-methoxy,4-hydroxy,5-iodo)cinnamoyl-(3’,4’-
dihydroxyphenyl)ketone; Tyrphostin I-OMe-AG 538]
A cell-permeable and reversible analog of AG 538 (Cat. No.658403) that
B9310 M y n/d n/d
83 c-Abl A5844 M y y y
84 c-Cbl C9603 P y n/d n/d
85 c-erbB-2 E2777 M y n/d n/d
86 c-erbB-3 E8767 M y n/d n/d
87 c-erbB-4 E5900 M y n/d n/d
88 phospho-c-Jun (pSer63) J2128 P y
033724.2 M y y y
84 c-Cbl C9603 P y n/d n/d
85 c-erbB-2 E2777 2064 ERBB2 NP_004439.2 M y n/d n/d
86 c-erbB-3 E8767 2065 ERBB3 NP_001973.2 M y n/d n/d
87 c-erbB-4 E5900 2066 ERBB4 NP_005226.1 M y n/d n/d
88